Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations by Rosell Rafael, Molina Miguel Angel, Costa Carlota, Simonetti Sara, Gimenez-Capitan Ana, Bertran-Alamillo Jordi, Mayo Clara, Moran Teresa, Mendez Pedro, Cardenal Felipe, Isla Dolores, Provencio Mariano, Cobo Manuel, Insa Amelia, Garcia-Campelo Rosario, Reguart Noemi, Majem Margarita, Viteri Santiago, Carcereny Enric, Porta Ruth, Massuti Bartomeu, Queralt Cristina, de Aguirre Itziar, Sanchez Jose Miguel, Sanchez-Ronco Maria, Mate Jose Luis, Ariza Aurelio, Benlloch Susana, Sanchez Jose Javier, Bivona Trever G, Sawyers Charles L, Taron Miquel in Clinical cancer research : an official journal of the American Association for Cancer Research (2011).

[PMID: 21233402] PubMed


Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated with erlotinib. However, the presence of EGFR mutations can only imperfectly predict outcome. We hypothesized that progression-free survival could be influenced both by the pretreatment EGFR T790M mutation and by components of DNA repair pathways.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.